KR102238379B1 - 감소된 산화를 갖는 제제 - Google Patents
감소된 산화를 갖는 제제 Download PDFInfo
- Publication number
- KR102238379B1 KR102238379B1 KR1020157027939A KR20157027939A KR102238379B1 KR 102238379 B1 KR102238379 B1 KR 102238379B1 KR 1020157027939 A KR1020157027939 A KR 1020157027939A KR 20157027939 A KR20157027939 A KR 20157027939A KR 102238379 B1 KR102238379 B1 KR 102238379B1
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- formulation
- compound
- hydroxyl
- oxidation
- Prior art date
Links
- 0 *c1c(*)[n]c2c(*)c(*)c(*)c(*)c12 Chemical compound *c1c(*)[n]c2c(*)c(*)c(*)c(*)c12 0.000 description 4
- YGPSJZOEDVAXAB-UHFFFAOYSA-N NC(CC(c(cccc1)c1N)=O)C(O)=O Chemical compound NC(CC(c(cccc1)c1N)=O)C(O)=O YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 1
- UONVFNLDGRWLKF-UHFFFAOYSA-N Nc(cc1)cc(C(O)=O)c1N Chemical compound Nc(cc1)cc(C(O)=O)c1N UONVFNLDGRWLKF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217009995A KR102317151B1 (ko) | 2013-03-13 | 2014-03-13 | 감소된 산화를 갖는 제제 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780852P | 2013-03-13 | 2013-03-13 | |
US61/780,852 | 2013-03-13 | ||
US201361909850P | 2013-11-27 | 2013-11-27 | |
US61/909,850 | 2013-11-27 | ||
PCT/US2014/026850 WO2014160497A1 (en) | 2013-03-13 | 2014-03-13 | Formulations with reduced oxidation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217009995A Division KR102317151B1 (ko) | 2013-03-13 | 2014-03-13 | 감소된 산화를 갖는 제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150130396A KR20150130396A (ko) | 2015-11-23 |
KR102238379B1 true KR102238379B1 (ko) | 2021-04-09 |
Family
ID=51625443
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217009995A KR102317151B1 (ko) | 2013-03-13 | 2014-03-13 | 감소된 산화를 갖는 제제 |
KR1020157027939A KR102238379B1 (ko) | 2013-03-13 | 2014-03-13 | 감소된 산화를 갖는 제제 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217009995A KR102317151B1 (ko) | 2013-03-13 | 2014-03-13 | 감소된 산화를 갖는 제제 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP2968467B1 (es) |
JP (2) | JP6606059B2 (es) |
KR (2) | KR102317151B1 (es) |
CN (1) | CN105209058A (es) |
BR (1) | BR112015022475A8 (es) |
CA (2) | CA3135558A1 (es) |
DK (1) | DK2968467T3 (es) |
ES (1) | ES2808823T3 (es) |
HK (1) | HK1212613A1 (es) |
HR (1) | HRP20201161T1 (es) |
HU (1) | HUE049707T2 (es) |
LT (1) | LT2968467T (es) |
MX (1) | MX370416B (es) |
PL (1) | PL2968467T3 (es) |
PT (1) | PT2968467T (es) |
RS (1) | RS60534B1 (es) |
RU (2) | RU2019137020A (es) |
SI (1) | SI2968467T1 (es) |
WO (1) | WO2014160497A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ739780A (en) | 2015-08-18 | 2024-02-23 | Rakuten Medical Inc | Compositions, combinations and related methods for photoimmunotherapy |
EP3777978A1 (en) * | 2015-08-18 | 2021-02-17 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
WO2020033485A1 (en) * | 2018-08-08 | 2020-02-13 | Genentech, Inc. | Use of tryptophan derivatives and l-methionine for protein formulation |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
AU668423B2 (en) | 1992-08-17 | 1996-05-02 | Genentech Inc. | Bispecific immunoadhesins |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
RU2134120C1 (ru) * | 1995-06-26 | 1999-08-10 | Безруков Михаил Васильевич | Средство для стабилизации пептидной связи в белковом препарате |
CA2264177C (en) | 1996-08-30 | 2015-03-17 | Upfront Chromatography A/S | Isolation of immunoglobulins |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
DK1167537T3 (da) | 1999-03-30 | 2008-11-10 | Japan Tobacco Inc | Fremgangsmåde til fremstilling af et monoklonalt antistof |
PT1491208E (pt) * | 1999-10-04 | 2010-05-12 | Novartis Vaccines & Diagnostic | Composições farmacêuticas contendo polipéptido líquidas estabilizadas |
KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
JP2001165858A (ja) * | 1999-12-06 | 2001-06-22 | Bunshi Biophotonics Kenkyusho:Kk | 5−アルコキシインドール類の測定方法及び装置 |
EP1463522A4 (en) | 2001-05-16 | 2005-04-13 | Einstein Coll Med | HUMAN ANTI-PNEUMOCOCCAL ANTIBODIES FROM NON-HUMAN ANIMALS |
RS51829B (sr) | 2001-08-23 | 2012-02-29 | Genmab A/S. | Ljudska antitela specifična za interleukin 15 (il-15) |
EP1539212A4 (en) * | 2002-07-12 | 2007-05-02 | Medarex Inc | METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS |
AU2004205898B2 (en) | 2003-01-17 | 2009-11-19 | The Research Foundation Of State University Of New York | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
JP4999158B2 (ja) | 2003-05-21 | 2012-08-15 | メダレツクス・インコーポレーテツド | 炭疽菌(bachillusanthracis)の感染防御抗原に対するヒトモノクローナル抗体 |
CN101074208A (zh) * | 2007-06-29 | 2007-11-21 | 方炳良 | 吲哚衍生物的制备方法 |
RU2414237C2 (ru) * | 2008-04-30 | 2011-03-20 | Государственное образовательное учреждение высшего профессионального образования "Удмуртский государственный университет" | Модификация альбумина совиалем как способ повышения его стабильности для производства фармацевтического биопрепарата альбумина в комплексе с гентамицином или стимаденом |
MX2011002372A (es) | 2008-09-10 | 2011-04-04 | Genentech Inc | Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas. |
BR112015022484A2 (pt) * | 2013-03-13 | 2017-07-18 | Genentech Inc | formulações com oxidação reduzida |
-
2014
- 2014-03-13 CA CA3135558A patent/CA3135558A1/en not_active Abandoned
- 2014-03-13 KR KR1020217009995A patent/KR102317151B1/ko active IP Right Grant
- 2014-03-13 BR BR112015022475A patent/BR112015022475A8/pt not_active Application Discontinuation
- 2014-03-13 RU RU2019137020A patent/RU2019137020A/ru unknown
- 2014-03-13 SI SI201431625T patent/SI2968467T1/sl unknown
- 2014-03-13 DK DK14776479.9T patent/DK2968467T3/da active
- 2014-03-13 JP JP2016502264A patent/JP6606059B2/ja active Active
- 2014-03-13 PT PT147764799T patent/PT2968467T/pt unknown
- 2014-03-13 RS RS20200848A patent/RS60534B1/sr unknown
- 2014-03-13 LT LTEP14776479.9T patent/LT2968467T/lt unknown
- 2014-03-13 WO PCT/US2014/026850 patent/WO2014160497A1/en active Application Filing
- 2014-03-13 MX MX2015011433A patent/MX370416B/es active IP Right Grant
- 2014-03-13 CA CA2904169A patent/CA2904169C/en active Active
- 2014-03-13 CN CN201480027210.8A patent/CN105209058A/zh active Pending
- 2014-03-13 HU HUE14776479A patent/HUE049707T2/hu unknown
- 2014-03-13 RU RU2015143549A patent/RU2707550C2/ru active
- 2014-03-13 PL PL14776479T patent/PL2968467T3/pl unknown
- 2014-03-13 ES ES14776479T patent/ES2808823T3/es active Active
- 2014-03-13 KR KR1020157027939A patent/KR102238379B1/ko active IP Right Grant
- 2014-03-13 EP EP14776479.9A patent/EP2968467B1/en active Active
-
2016
- 2016-01-20 HK HK16100589.9A patent/HK1212613A1/zh unknown
-
2019
- 2019-05-08 JP JP2019088239A patent/JP2019167349A/ja active Pending
-
2020
- 2020-07-24 HR HRP20201161TT patent/HRP20201161T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BR112015022475A8 (pt) | 2019-11-26 |
SI2968467T1 (sl) | 2020-11-30 |
JP2019167349A (ja) | 2019-10-03 |
HRP20201161T1 (hr) | 2020-11-13 |
LT2968467T (lt) | 2020-08-25 |
CA3135558A1 (en) | 2014-10-02 |
KR20150130396A (ko) | 2015-11-23 |
CN105209058A (zh) | 2015-12-30 |
CA2904169A1 (en) | 2014-10-02 |
HK1212613A1 (zh) | 2016-06-17 |
JP6606059B2 (ja) | 2019-11-13 |
RU2707550C2 (ru) | 2019-11-27 |
HUE049707T2 (hu) | 2020-11-30 |
WO2014160497A1 (en) | 2014-10-02 |
CA2904169C (en) | 2021-12-07 |
RU2015143549A (ru) | 2017-04-20 |
RS60534B1 (sr) | 2020-08-31 |
EP2968467A1 (en) | 2016-01-20 |
EP2968467B1 (en) | 2020-06-03 |
PT2968467T (pt) | 2020-07-28 |
ES2808823T3 (es) | 2021-03-02 |
KR102317151B1 (ko) | 2021-10-26 |
KR20210040190A (ko) | 2021-04-12 |
DK2968467T3 (da) | 2020-08-10 |
EP2968467A4 (en) | 2016-09-21 |
BR112015022475A2 (pt) | 2017-07-18 |
MX370416B (es) | 2019-12-10 |
MX2015011433A (es) | 2016-04-27 |
RU2019137020A (ru) | 2021-01-14 |
JP2016513667A (ja) | 2016-05-16 |
PL2968467T3 (pl) | 2020-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230181533A1 (en) | Formulations with reduced oxidation | |
AU2019202464B2 (en) | Formulations with reduced oxidation | |
JP7046814B2 (ja) | タンパク質製剤のためのトリプトファン誘導体の使用 | |
JP2016520521A5 (es) | ||
JP2019167349A (ja) | 酸化還元製剤 | |
US10653779B2 (en) | Formulations with reduced oxidation | |
NZ751543B2 (en) | Formulations with reduced oxidation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
A107 | Divisional application of patent | ||
GRNT | Written decision to grant |